---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-016684"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:48:45.816710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports Q1 net loss $29.1M, cash $86.7M plus $172.5M offering; positive Phase II diabetes data

## Summary
- Net loss $29.1M vs $16.4M in Q1 2022; R&D expense $24.4M (up from $11.4M).
- Cash $86.7M at Mar 31, 2023; plus $172.5M gross from April offering to ≈$259M total.
- COVALENT-111 Phase II Cohort 3 (100 mg): 89% of patients had HbA1c reduction, 56% had ≥1% reduction.
- IND cleared for BMF-500; Phase I COVALENT-103 for FLT3-mutant acute leukemias to start enrolling.
- Initial AML/ALL data from COVALENT-101 expected in Q2 2023.

## SEC filing metadata
- accession: 0000950170-23-016684
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/0000950170-23-016684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/bmea-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-016684
- JSON: https://secwatch.observer/filing/0000950170-23-016684.json
- Plain text: https://secwatch.observer/filing/0000950170-23-016684.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 2, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000095017023016684/0000950170-23-016684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.